High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone

European Journal of Endocrinology

Volumn 153, Issue 1, 2005, Pages 107-113

  Mueller, Andreas ^b   Dittrich, Ralf ^b   Binder, Helge ^b   Kuehnel, Werner ^a   Maltaris, Theodoros ^b   Hoffmann, Inge ^b   Beckmann, Matthias ^b  

^a DPC Academy   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DEOXYPYRIDINOLINE; ESTRADIOL VALERATE; ESTROGEN; GLUCOCORTICOID; GONADORELIN AGONIST; GOSERELIN; OSTEOCALCIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TRANSSEXUALISM; URINE LEVEL;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; ESTROGENS; FEMALE; FEMUR NECK; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE; TRANSSEXUALISM;

EID: 22744445113     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01943     Document Type: Article

References (47)

1. Greendale GA, Edelstein S & Barret-Conner E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. Journal of Bone and Mineral Research 1997 12 1833-1843.
2. Center JR, Nguyen TV, Sambrook PN & Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. Journal of Clinical Endocrinology and Metabolism 1999 84 3626-3635.
3. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW & Felson DT. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Annals of Internal Medicine 2000 133 951-963.
4. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R & Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. Journal of Clinical Investigation 2000 106 1553-1560.
5. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubhan DB & Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England Journal of Medicine 1994 331 1056-1061.
6. Morishima A, Grumbach MM, Simpson ER, Fisher C & Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Journal of Clinical Endocrinology and Metabolism 1995 80 3689-3698.
7. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS & Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 1997 337 91-95.
8. Bilezikan JP, Morishima A, Bell J & Brumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. New England Journal of Medicine 1998 339 599-603.
9. Khosla S, Melton III J, Atkinson EJ & O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. Journal of Clinical Endocrinology and Metabolism 2001 86 3555-3561.
10. Välimäki V, Alfthan H, Ivaska K, Pettersson LK, Stenman UH & Välimäki M. Serum estradiol, testosterone, and sex hormone-binding globulin as regulators of peak bone mass and bone turnover rate in young Finnish men. Journal of Clinical Endocrinology and Metabolism 2004 89 3785-3789.
11. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG & Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. Journal of Clinical Endocrinology and Metabolism 1998 83 2266-2274.
12. Slemenda CW Longcope C, Zhou L, Hui SL, Peacock M & Johnston CC. Sex steroids and bone mass in older man: positive associations with serum estrogens and negative associations with androgens. Journal of Clinical Investigation 1997 100 1755-1759.
13. Hamburger C. Endocrine treatment of male and female transsexualism. In Transsexualism and sex reassignment, pp 291-307. Eds R Green & J Money. Baltimore: John Hopkins Press, 1969.
14. The Harry Benjamin International Gender Dysphoria Association standards of care for gender identity disorders, 6th version 2001. http://www.hbigda.org/soc.html. Retrieved 2002, November 17.
15. Moore E, Wisniewski A & Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism 2003 88 3467-3473.
16. Levy A, Crown A & Reid R. Endocrine intervention for transsexuals. Clinical Endocrinology 2003 59 409-418.
17. Schlatterer K, Auer DP, Yassouridis A, von Werder K & Stalla GK. Transsexualism and osteoporosis. Experimental and Clinical Endocrinology and Diabetes 1998 106 365-368.
18. van Kesteren P, Lips P, Gooren LJ, Asscheman H & Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology 1998 48 347-354.
19. Bonjour JP, Theintz G, Buchs B, Slosman D & Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. Journal of Clinical Endocrinology and Metabolism 1991 73 555-563.
20. Kuhl H. Pharmacology of estradiol and estriol. Menopause Review 2000 5 23-44.
21. Aedo AR, Landgren BM & Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women. Maturitas 1990 12 333-343.
22. Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH & Pols HA. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. Journal of Clinical Endocrinology and Metabolism 2004 89 3261-3269.
23. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N & Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clinical Endocrinology 1998 49 803-809.
24. Klein KO, Larmore KA, de Lancey E, Brown JM, Considine RV & Hassink SG. Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. Journal of Clinical Endocrinology and Metabolism 1998 83 3469-3475.
25. Lorentzon M, Lorentzon R, Backstrom T & Nordstrom P. Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study. Journal of Clinical Endocrinology and Metabolism 1999 84 4597-4601.
26. Vermeulen A, Kaufman JM, Goemaere S & van Pottelberg I. Estradiol in elderly men. Aging Male 2002 5 98-102.
27. van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J & Gooren L. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. Journal of Clinical Endocrinology and Metabolism 1996 81 2227-2232.
28. Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treatment Reviews 2003 29 211-218.
29. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW & Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 2001 345 948-955.
30. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM & Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. Journal of Urology 1999 161 1219-1222.
31. Diamond T, Campbell J, Bryant C & Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998 83 1561-1566.
32. Townsend MF, Sanders WH, Northway RO & Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997 79 545-550.
33. Hatano T, Oishi Y, Furuta A, Iwamuro S & Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU International 2000 86 449-452.
34. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H & Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. Journal of Urology 2001 166 1724-1728.
35. Smith MR. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology 2003 18 (Suppl 3) 21-25.
36. Doran PM, Riggs BL, Atkinson EJ & Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. Journal of Bone and Mineral Research 2001 16 2118-2125.
37. Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T & Kumon H. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004 64 128-131.
38. Eriksson S, Eriksson A, Stege R & Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcified Tissue International 1995 57 97-99.
39. Smith MR, Fallon MA, Lee H & Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 3841-3846.
40. Ju HS, Leung S, Brown B, Stringer MA, Leigh S, Scherrer C, Shepard K, Jenkins D, Knudsen J & Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clinical Chemistry 1997 43 1570-1576.
41. Paoletti AM, Orru M, Lello S, Floris S, Ranuzzi F, Etzi R, Zedda P, Guerriero S, Fratta S, Sorge R, Mallarini G & Melis GB. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception 2004 70 293-298.
42. Grinspoon SK, Friedman AJ, Miller KK, Lippman J, Olson WH & Warren MP. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism 2003 88 3651-3656.
43. Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M & Di Carlo C. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003 67 355-359.
44. Grinspoon S, Thomas L, Miller K, Herzog D & Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2002 87 2883-2891.
45. Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE & Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 2003 68 177-182.
46. Speroff L, Rowan J, Symons J, Genant H & Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996 276 1397-1403.
47. Doren M, Nilsson JA & Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Human Reproduction 2003 18 1737-1746.